Elsevier Launches Inteleos Drug Tracking and Analysis Tool
Amsterdam, 27 March 2006 – Elsevier, a world-leading healthcare and scientific publisher, announced today the launch of its new drug tracking and analysis tool, Inteleos. To meet the demanding requirements of business intelligence, market research and business development professionals, Elsevier has developed a database of over 8,000 drugs and 1,200 pharmaceutical and biotech companies. The database also includes medical conference news from Elsevier’s IMNG, weekly updates from The Pink Sheets, and ontology files of 1.25 million terms to enhance searching.
With Inteleos, users can track and analyse drug activity from late-phase preclinical development through to launch and post-marketing studies. Users can also monitor licensing, or merger and acquisition activities with ease. Inteleos offers a unique combination of features and functionality to help users save valuable time and increase efficiency.
“Our team has shown real commitment to customer focus in bringing Inteleos to market,” says Brian Nairn, CEO of Elsevier Health Sciences. “The customer experience is at the core of everything that we do. From the beginning, we’ve worked to develop tools that enable intelligence professionals to make actionable business decisions. Extensive user testing tells us, Inteleos is doing the job it was designed to do.” The Inteleos editorial team adheres to strict editorial guidelines. The database is updated daily using only primary sources direct from drug companies, regulatory agencies, or financial filings.
In addition to breadth and depth of coverage, the Inteleos interface is clean and easy to use. “Users can personalize the search experience with tools that facilitate easy organization and monitoring of drugs, companies and therapy areas,” explains Julie Gordon, Director of Emerging Products. “They have the flexibility to run simple or complex searches using a wide set of parameters and the ability to quickly and easily develop graphical representations of scenarios with state-of-the-art analysis tools.”
A select group of customers will have immediate access to Inteleos. The database will be available commercially in May 2006.
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com
Phone: +31 20 3051380